Radium-223 dichloride, trade name Xofigo, is a radiopharmaceutical approved for the treatment of patients with symptomatic bone metastases and no visceral disease from prostate cancer resistant to anti androgen therapy. The molecule mimics calcium and forms a complex with hydroxyapatite at sites...